Alpha-1 Antitrypsin Deficiency (AATD) Clinical Trials

Find Alpha-1 Antitrypsin Deficiency (AATD) Clinical Trials Near You

A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

Status: Recruiting
Location: See all (12) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This is a Phase 1/2, multicenter, open-label study conducted in 3 parts (Part A, Part B, and Part C) to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease. Parts A and B are designed to evaluate safety and tolerability and identify the optimal biological dose (OBD) in patients with AATD-associated lung disease (Part A) and/or liver disease (Part B), with optional expansion cohorts to further evaluate a potential OBD. Part C is designed to demonstrate the efficacy and safety of BEAM-302 at the OBD in patients with AATD-associated lung disease with or without liver disease in the pivotal cohort.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Age 18-70 years.

• Confirmed PiZZ AATD diagnosis.

• Blood total AAT level \<11 μM.

• Willing to discontinue augmentation therapy as required by protocol.

• A postbronchodilator FEV1 ≥40% (Ph 1) of predicted or ≥35% (Ph 2) and an FEV1/FVC \<70% at screening (Ph 1 only).

• Evidence of emphysema on chest imaging.

• Age 18-70 years.

• Confirmed PiZZ AATD diagnosis.

• Clinical diagnosis of AATD-related liver disease along with evidence of METAVIR F1, F2, or F3 liver fibrosis.

• A postbronchodilator FEV1 ≥40% (Phase 1) or ≥35% (Phase 2) of predicted at screening.

• FibroScan ≤12 kPa.

• Age 18-75 years.

• Confirmed PiZZ AATD diagnosis.

• Willing to discontinue augmentation therapy as required by protocol.

• A postbronchodilator FEV1 ≥30% of predicted.

• Evidence of emphysema chest imaging.

• Liver stiffness \<12 kPa.

Locations
United States
Alabama
Clinical Study Center
RECRUITING
Birmingham
Massachusetts
Clinical Study Center
RECRUITING
Boston
South Carolina
Clinical Study Center
RECRUITING
Charleston
Other Locations
Australia
Clinical Study Center
RECRUITING
Adelaide
Clinical Study Center
RECRUITING
Fitzroy
Ireland
Clinical Study Center
RECRUITING
Dublin
Netherlands
Clinical Study Center
RECRUITING
Leiden
New Zealand
Clinical Study Center
RECRUITING
Auckland
Clinical Study Center
RECRUITING
Hamilton
United Kingdom
Clinical Study Center
RECRUITING
Birmingham
Clinical Study Center
RECRUITING
London
Clinical Study Center
RECRUITING
Southampton
Contact Information
Primary
Medical Information
clinicalinfo@beamtx.com
857-327-8641
Time Frame
Start Date: 2024-06-19
Estimated Completion Date: 2030-05
Participants
Target number of participants: 192
Treatments
Experimental: BEAM-302 Drug Product
Sponsors
Leads: Beam Therapeutics Inc.

This content was sourced from clinicaltrials.gov